79.37

0.78% -0.62

Pre-market: 79.50 0.13 +0.16%

Celcuity Inc (CELC)

Overview News Price History Option Chain Financials Discussions Forecast

Celcuity Inc stock is traded at $79.37, with a volume of 971.26K. It is down -0.78% in the last 24 hours and down -12.58% over the past month. Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Previous Close:

$79.99

Open:

$79.73

24h Volume:

971.26K

Relative Volume:

0.83

Market Cap:

$3.88B

Revenue:

Net Income/Loss:

$-192.89M

P/E Ratio:

-20.36

EPS:

-3.8976

Net Cash Flow:

$-172.97M

1W Performance:

-6.52%

1M Performance:

-12.58%

6M Performance:

-22.19%

1Y Performance:

+47.03%

1-Day Range:

$77.07

$80.19

1-Week Range:

$77.07

$85.50

52-Week Range:

$44.42

$151.02

Celcuity Inc Stock (CELC) Company Profile

Name

Celcuity Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

763-392-0767

Address

16305 36TH AVENUE N, MINNEAPOLIS, MN

Employee

155

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

CELC's Discussions on Twitter

Compare CELC vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CELC Celcuity Inc	79.37	3.88B	0	-192.89M	-172.97M	-3.8976
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Celcuity Inc Stock (CELC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-27-26	Initiated	Citizens	Mkt Outperform
Dec-12-25	Initiated	Wells Fargo	Overweight
Nov-18-25	Initiated	Wolfe Research	Outperform
Nov-17-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-22-25	Initiated	Guggenheim	Buy
Jul-01-25	Resumed	Stifel	Buy
Jul-22-24	Initiated	Leerink Partners	Outperform
Feb-22-24	Initiated	Stifel	Buy
Dec-08-23	Initiated	H.C. Wainwright	Buy
Oct-08-21	Initiated	Canaccord Genuity	Buy
Sep-07-21	Initiated	Jefferies	Buy
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy
Jan-28-21	Reiterated	H.C. Wainwright	Buy
Dec-24-20	Reiterated	H.C. Wainwright	Buy
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy

View All

Celcuity Inc Stock (CELC) Latest News

Sep 20, 2026

CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Stocktwits

Sep 20, 2026

Sep 18, 2026

Celcuity Inc.Common Stock (NQ: CELC - The Chronicle-Journal

Sep 18, 2026